# Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

> **NCT02294656** · PHASE1 · COMPLETED · sponsor: **Soll Eye** · enrollment: 4 (actual)

## Conditions studied

- CYSTOID MACULAR EDEMA

## Interventions

- **DRUG:** Ranibizumab,
- **DRUG:** Triamcinolone acetonide

## Key facts

- **NCT ID:** NCT02294656
- **Lead sponsor:** Soll Eye
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2018-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02294656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02294656, "Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02294656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*